Renal Cell Carcinoma
Studies from University of Washington, Division of Medical Oncology in the area of renal cell carcinoma published
Published in Cancer Weekly, June 1st, 2010
New research, 'Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study,' is the subject of a report. "Single-agent PF-3512676 (agatolimod), a Toll-like receptor 9 agonist, was examined in an open-label, single-arm, multicenter phase I/II study to determine its maximum tolerated dose (MTD), safety profile, antitumor activity, pharmacokinetics, and immunologic effects in patients with advanced metastatic renal cell carcinoma (RCC). PF-3512676 was administered subcutaneously weekly for up to 24 weeks to 39 adults with stage IV RCC," scientists in the United States report.
"Patients were excluded if...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-06-01)
More Articles from Cancer Weekly
- Prostate Cancer
Scientists find protein spurs spread of prostate cancer - Pancreatic Cancer
Researchers from University of Nebraska Medical Center detail new studies and findings in the area of pancreatic cancer - Colon Cancer
Data on colon cancer published by researchers at University of North Carolina, Department of Epidemiology - Prostate Cancer
Reports outline prostate cancer research from University of Washington, Department of Urology - Bowel Cancer
Investigators at University of Warwick release new data on bowel cancer - Prostate Cancer
Findings from University of Colorado in prostate cancer reported - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
